Our Vision

We aim to help the outlook for individuals living with major Neurodegenerative diseases. Amongst the most prevalent conditions worldwide are Dementia (50 million) and Parkinson's Disease (7-8M). Disorders such as Progressive Multiple Sclerosis (PMS) and Motor Neuron Disease (MND), also known as Amyotrophic Lateral Sclerosis, are less common (3M in total) but have major societal and individual impact.

Over 1 million people are living with neurodegenerative disease in the UK alone. At present, there are partial symptomatic treatments available for some symptoms, but few, if any, effective disease-modifying therapies to delay or slow the disease process and certainly none that can lead to reversal. 

We will encourage and support the development, running and reporting of Multi-arm, Multi-stage (MAMS) Platform Trials in Neurodegenerative conditions. We will carry out research in four major neurodegenerative diseases: Motor Neuron Disease (MND), Progressive Multiple Sclerosis (MS), Parkinson’s Disease (PD) and, ultimately, Dementia.

Our Collaborators

We, under a programme of activity led by the ACORD collaboration, will bring together expertise in the field, linking organisations and researchers.

The projects themselves are led by those individuals who have the relevant disease expertise.

Forthcoming Meetings 

The inaugural meeting of the ACORD collaboration is to take place on Wednesday 8 June 2022.  The programme for the meeting includes:

  • Results from the first stage of the MAMS trial in motor neuron disease, MND-SMART
  • Details of the planned MAMS trial in multiple sclerosis (OCTOPUS)
  • Rapidly developing plans for Parkinson’s and Alzheimer’s trials
  • How these initiatives fit into and complement initiatives in other countries worldwide 

There will be considerable opportunity for discussion and networking on the day and we are looking forward to it.


Our neurodegenerative diseases studies


A collaboration of groups developing, running and reporting multi-arm multi-stage trials in neurodegenerative diseases


The MND-SMART trial is an innovative, currently recruiting UK clinical trial testing two potential new treatments for Motor Neuron Disease (MND)


The OCTOPUS trial in Progressive Multiple Sclerosis (MS); the first ever multi-arm, multi-stage trial for progressive MS


The EJS ACT-PD trial, a multi-arm multi-stage platform for evaluating new therapies for Parkinson’s Disease (PD)